Seems to have all it takes......The trial met both its primary efficacy endpoints, with a vaccine efficacy (VE) of 83.7% (95.88% CI: 66.1%, 92.2%; p<0.0001) against RSV-LRTD as defined by two or more symptoms, and a VE of 82.4% (96.36% CI: 34.8%, 95.3%; p=0.0078) against RSV-LRTD defined by three or more symptoms.
Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts
The Moderna buying spree this year began on March 11. Ark was a buyer again on March 12 before pausing purchases on March 13 and 14. It resumed buying on Friday, March 15, and added more of the stock on Monday, Tuesday, and Wednesday.
News 
Market Data 
Discover 
